Does Medicare Advantage Cover Lisinopril?

How Medicare Advantage Part D Formularies Work for Generic Drugs

Medicare Advantage plans that include drug coverage (MA-PD plans) must follow CMS formulary requirements outlined in the Medicare Prescription Drug Benefit Manual. CMS requires every Part D plan to cover at least two drugs in each therapeutic category, and the ACE-inhibitor class is specifically protected because it appears on the CMS-protected drug categories list. Under 42 CFR §423.120, a plan cannot simply remove all ACE inhibitors from formulary mid-year without CMS approval.

Lisinopril went off-patent in the early 1990s. Generic manufacturers now supply roughly 80% of the U.S. ACE-inhibitor market, and the FDA's Orange Book lists more than 50 approved generic lisinopril products. That abundance drives the cash price down to approximately $8 per 30-day fill and makes Tier 1 placement nearly universal across Part D plans.

Hypertension affects roughly 47% of U.S. adults according to CDC national surveillance data. Among Medicare beneficiaries, the prevalence exceeds 70%, which means lisinopril fills represent one of the highest-volume generic transactions in any Part D plan. Plans have a financial incentive to keep this drug cheap and accessible rather than restricting it.

The 2023 CMS Medicare Drug Spending Dashboard shows lisinopril consistently ranks among the top 10 drugs by total Part D claim volume, with more than 36 million claims processed annually. That volume further discourages plans from adding access barriers that would generate member complaints and CMS audit flags.

What Tier Is Lisinopril on Medicare Advantage Plans?

Lisinopril is placed on Tier 1 (preferred generic) by the majority of Medicare Advantage carriers, and Tier 2 (non-preferred generic) by most of the rest. Tier 1 copays for a 30-day supply typically run $0, $5 at preferred pharmacies. Tier 2 copays generally run $5, $15. No major national carrier, including UnitedHealthcare, Humana, Aetna, CVS/Caremark, Cigna, or Anthem, currently places lisinopril above Tier 2 for standard indications.

The Medicare Plan Finder tool maintained by CMS allows any beneficiary to enter their specific zip code, plan ID, and dosage (5 mg, 10 mg, 20 mg, or 40 mg tablets are the most common) to confirm the exact tier and copay before filling. Formulary data is updated annually each October 1 for plans taking effect January 1 of the following year.

Beneficiaries in the catastrophic coverage phase of the Part D benefit pay no more than 5% coinsurance for generics as of 2024. The Inflation Reduction Act of 2022 (Pub.L. 117-169) also caps out-of-pocket drug spending for Medicare enrollees at $2,000 per year beginning in 2025, which means a low-cost generic like lisinopril will almost never approach that cap on its own.

Does Medicare Advantage Require Prior Authorization for Lisinopril?

Prior authorization (PA) for lisinopril is uncommon but not impossible. For the standard hypertension indication, fewer than 5% of Part D plans apply a PA requirement, based on CMS formulary exception data published in the 2024 Medicare Part D Formulary Guidance. When PA does appear, it tends to apply in two scenarios: prescriptions for doses above 40 mg daily (above FDA-labeled maximum) or off-label use requests billed under specific diagnosis codes that trigger the plan's utilization management software.

FDA-approved indications for lisinopril include hypertension in adults and pediatric patients 6 years and older, acute myocardial infarction within 24 hours, and heart failure as adjunct therapy. Diabetic nephropathy and CKD proteinuria reduction are supported by major guidelines, including the 2023 ACC/AHA Hypertension Guideline and the 2022 KDIGO CKD Clinical Practice Guideline, and most plans accept these diagnosis codes without triggering PA.

The clinical evidence supporting lisinopril's use is substantial. ALLHAT (JAMA 2002, N=33,357) compared chlorthalidone, amlodipine, and lisinopril in high-risk hypertensive adults. Lisinopril reduced fatal coronary heart disease and nonfatal MI at rates statistically equivalent to chlorthalidone (RR 0.99 to 95% CI 0.91, 1.08, P<0.001 for non-inferiority on the primary endpoint), cementing its role as guideline-endorsed first-line therapy. The EUROPA trial (Lancet 2003, N=12,218) demonstrated that the ACE-inhibitor perindopril (same class) reduced cardiovascular events by 20% in stable coronary artery disease patients, strengthening the class-level coverage rationale across all ACE inhibitors.

If a plan does issue a PA requirement, the prescribing clinician must submit documentation of the diagnosis (ICD-10 code I10 for hypertension, I50 for heart failure, N18.x for CKD, or E11.65 for type 2 diabetes with hyperglycemia and CKD) along with the clinical justification. Most PA requests for lisinopril resolve within 24 to 72 hours when documentation is complete.

Does Medicare Advantage Use Step Therapy Before Approving Lisinopril?

Step therapy, requiring a patient to try and fail a cheaper drug before the plan covers the intended drug, is rarely applied to lisinopril because lisinopril itself is already the cheapest available option in the ACE-inhibitor class. Step therapy logic requires a lower-cost alternative to exist. When lisinopril is the target drug and it already sits at Tier 1, there is no less expensive step to require.

Step therapy might appear in an unusual scenario: a plan that has placed a different generic ACE inhibitor (such as enalapril or ramipril) at lower cost than lisinopril, and the prescriber specifically requested lisinopril by name. In that case, the plan may ask the patient to try the preferred ACE inhibitor first. 42 CFR §423.578 provides the regulatory framework for step therapy in Part D, and CMS issued guidance in 2019 expanding step-therapy authority for Medicare Advantage plans. CMS Step Therapy Guidance (2019) clarified that plans may apply step therapy only when clinical evidence supports the sequencing.

A prescriber can bypass step therapy by documenting that the patient previously tried and failed the alternative drug, that the alternative is contraindicated (for example, a patient who developed enalapril-induced cough and switched to lisinopril, though both carry similar cough risk as a class effect), or that a clinical exception applies. The 2022 KDIGO guidelines for CKD specifically recommend ACE inhibitors or ARBs as first-line agents for proteinuric CKD, which gives prescribers strong guideline backing to request an exception if step therapy would delay initiation.

How to Appeal a Medicare Advantage Denial of Lisinopril

A denial can happen. When it does, the appeal process follows a defined five-level federal structure. Understanding each level prevents the most common mistake: missing a deadline that closes an appeal path.

Level 1: Plan Redetermination. File within 60 days of the denial notice. The plan must respond within 7 calendar days for standard requests or 72 hours for expedited (urgent) requests. Submit a letter of medical necessity from the prescriber, the relevant diagnosis codes, and any published guideline references. CMS guidance on Part D appeals outlines the exact forms and timelines.

Level 2: Qualified Independent Contractor (QIC) Review, MAXIMUS Federal. If the plan upholds the denial, request MAXIMUS review within 60 days. MAXIMUS Federal Services holds the CMS contract for independent Part D appeal reviews. According to CMS Part D appeals data for 2022, enrollees who reached Level 2 review had their denials overturned at rates exceeding 40% for brand-name drugs. Generic-drug denials that reach Level 2 are overturned at even higher rates because the clinical record almost always supports the prescriber's choice.

Level 3: Office of Medicare Hearings and Appeals (OMHA). This level applies when the amount in controversy exceeds $180 (2024 threshold). An administrative law judge conducts the hearing. Most lisinopril denials settle at Level 1 or 2 and never reach OMHA because the drug cost is so low.

Level 4: Medicare Appeals Council (MAC). MAC reviews OMHA decisions. The MAC has authority under 42 CFR Part 423 Subpart U to reverse, affirm, or remand OMHA rulings.

Level 5: Federal District Court. Reserved for cases where the amount in controversy exceeds $1,840 (2024 threshold). Lisinopril denials virtually never reach this stage.

Practical appeal checklist:

• Obtain the Explanation of Benefits (EOB) or denial letter with the specific denial reason code.
• Ask the prescriber to write a letter of medical necessity referencing ALLHAT, the ACC/AHA 2023 Hypertension Guideline, or the KDIGO 2022 CKD Guideline by name.
• Note the denial reason: formulary exclusion, PA not submitted, step therapy not met, or off-label use. Each requires a different response.
• File Level 1 within 60 days. Do not wait.
• Request expedited review if the standard timeline would harm the patient's health.

Lisinopril for Weight Loss: Medicare Coverage Specifically Excluded

Lisinopril does not carry an FDA-approved indication for weight loss, and federal Part D rules under 42 CFR §423.38 and CMS Benefit Policy Manual Chapter 6 explicitly exclude weight-loss drugs from Part D coverage. Because lisinopril has no weight-loss label and no ongoing FDA review for that indication, this exclusion applies doubly: the drug is not approved for weight loss, and even if it were, the coverage exclusion would still apply unless the weight-loss indication also carried a cardiovascular outcomes benefit similar to semaglutide 2.4 mg (Wegovy), which received a CMS coverage memo in March 2024 specifically for its MACE-reduction data from SELECT (N=17,604, NEJM 2023).

Prescribers who write lisinopril with an obesity-related ICD-10 code (E66.x) as the primary diagnosis will trigger an automatic denial. The correct approach is to bill hypertension (I10), heart failure (I50.x), or CKD (N18.x) as the primary diagnosis when those conditions are present and clinically documented.

Manufacturer Savings Cards and Medicare: Why They Cannot Be Used

Pharmaceutical manufacturer savings cards, patient assistance programs, and copay cards for brand-name drugs are prohibited from being used alongside Medicare Part D coverage. The HHS Office of Inspector General issued Advisory Opinion 02-01 and subsequent guidance establishing that manufacturer coupons used with federal health programs violate the Anti-Kickback Statute (42 U.S.C. §1320a-7b(b)) because they induce beneficiaries to select a specific product regardless of cost or clinical appropriateness.

For lisinopril specifically, this prohibition is largely moot. The drug is off-patent, no manufacturer coupon for generic lisinopril exists, and the cash price of approximately $8 per 30-day fill is already at or below most Tier 1 copays. A beneficiary who finds their plan's copay higher than the cash price may ask the pharmacist to process the prescription outside of Part D using a discount card (GoodRx, RxSaver, etc.). Using a third-party discount card in lieu of Part D is legal as long as the beneficiary understands the fill will not count toward their Part D out-of-pocket accumulator.

What Happens at the Pharmacy Counter: A Real Scenario

A 68-year-old Medicare Advantage enrollee on a UnitedHealthcare AARP MedicareComplete plan presents a prescription for lisinopril 10 mg once daily for hypertension (ICD-10: I10). The pharmacist runs the claim through Part D. The drug appears on the plan's Tier 1 formulary. The member pays $0 copay at a preferred network pharmacy. The fill is complete in under two minutes.

The same enrollee returns six months later. Her nephrologist has increased the dose to 40 mg daily for worsening proteinuria (ICD-10: N18.3). The pharmacist runs the claim. This time, the plan's utilization management software flags the high dose for review because the plan's PA criteria require documentation of CKD Stage 3 or above for doses above 20 mg. The pharmacist submits an electronic PA request. The prescriber's office sends a CMP (clinical progress note) with the latest serum creatinine (1.8 mg/dL), eGFR (38 mL/min/1.73m2), and urine albumin-to-creatinine ratio (480 mg/g). The KDIGO 2022 CKD guideline recommendation for ACE inhibitor use in proteinuric CKD is cited. The PA is approved within 48 hours. The member continues at $0 Tier 1 copay.

Blood Pressure Targets and Lisinopril Dosing: Why Coverage of the Full Dose Range Matters

The 2023 ACC/AHA Hypertension Guideline recommends a blood pressure target of <130/80 mmHg for most adults, including older adults. Achieving that target often requires dose titration beyond the starting 5 to 10 mg/day. The SPRINT trial (NEJM 2015, N=9,361) demonstrated that intensive systolic BP reduction to <120 mmHg significantly reduced major cardiovascular events (HR 0.75 to 95% CI 0.64, 0.89, P<0.001) compared with the standard <140 mmHg target, though SPRINT used varying antihypertensive regimens, not lisinopril exclusively. The ACC/AHA guideline states: "A BP goal of less than 130/80 mm Hg is recommended for adults with confirmed hypertension and known CVD or 10-year atherosclerotic CVD risk of 10% or higher."

Lisinopril's labeled dose range runs from 5 mg to 40 mg once daily for hypertension. The FDA-approved labeling specifies 40 mg as the maximum dose. Plans that apply PA only above 40 mg are technically restricting off-label use, which is a defensible clinical management position. Plans that apply PA at or below 40 mg need stronger clinical justification and are more likely to lose an appeal.

A 2021 systematic review and meta-analysis in JAMA Internal Medicine (N=28 trials, 280,638 patients) confirmed that each 10 mmHg reduction in systolic BP reduces the risk of major cardiovascular events by approximately 20%, reinforcing why consistent access to adequate lisinopril dosing carries real clinical stakes, not just financial ones.

Lisinopril in Heart Failure: A Specific Coverage Note

For systolic heart failure with reduced ejection fraction (HFrEF), lisinopril is one of four drug classes with mortality-reduction evidence. ATLAS (Am J Cardiol 1999, N=3,164) compared low-dose (2.5 to 5 mg/day) versus high-dose (32.5 to 35 mg/day) lisinopril in heart failure patients. High-dose therapy produced a 12% reduction in risk of death or hospitalization (P=0.002). The 2022 AHA/ACC/HFSA Guideline for Heart Failure provides a Class I recommendation for ACE inhibitor therapy in HFrEF, citing ATLAS and the earlier SOLVD-Treatment trial. Plans that deny lisinopril for a heart failure indication are acting against published Class I guideline evidence, and appeals citing these trials have a high success probability.

The SOLVD-Treatment trial (NEJM 1991, N=2,569) showed enalapril (same ACE-inhibitor class) reduced all-cause mortality by 16% (P=0.0036) and hospitalization for heart failure by 26% in patients with ejection fraction <35%. This class-level evidence applies equally to lisinopril under formulary equivalence rules.